• myGriffith
    • Staff portal
    • Contact Us⌄
      • Future student enquiries 1800 677 728
      • Current student enquiries 1800 154 055
      • International enquiries +61 7 3735 6425
      • General enquiries 07 3735 7111
      • Online enquiries
      • Staff phonebook
    View Item 
    •   Home
    • Griffith Research Online
    • Journal articles
    • View Item
    • Home
    • Griffith Research Online
    • Journal articles
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

  • All of Griffith Research Online
    • Communities & Collections
    • Authors
    • By Issue Date
    • Titles
  • This Collection
    • Authors
    • By Issue Date
    • Titles
  • Statistics

  • Most Popular Items
  • Statistics by Country
  • Most Popular Authors
  • Support

  • Contact us
  • FAQs
  • Admin login

  • Login
  • Targeted Drug Delivery to the Virus-Infected Airway; Complications and Remedies

    Thumbnail
    View/Open
    100508_1.pdf (543.1Kb)
    Author(s)
    Clarke, Daniel TW
    McMillan, Nigel AJ
    Griffith University Author(s)
    McMillan, Nigel
    Clarke, Daniel
    Year published
    2015
    Metadata
    Show full item record
    Abstract
    Drug delivery to the airway and lower respiratory tract by aerosol inhalation has become a successful,non-invasive method of preventing and treating local disease of the lung. Consequently, it has been a promising route for clinical trials using highly specific and novel therapies to overcome viral pulmonary infection such as RNA interference, neutralising monoclonal antibodies and microparticle treatments. Yet despite this great potential, this form of delivery has proven somewhat ineffective due to airway remodeling, inflammation and mucus hypersecretion that results from viral symptoms in the respiratory tract. Here we ...
    View more >
    Drug delivery to the airway and lower respiratory tract by aerosol inhalation has become a successful,non-invasive method of preventing and treating local disease of the lung. Consequently, it has been a promising route for clinical trials using highly specific and novel therapies to overcome viral pulmonary infection such as RNA interference, neutralising monoclonal antibodies and microparticle treatments. Yet despite this great potential, this form of delivery has proven somewhat ineffective due to airway remodeling, inflammation and mucus hypersecretion that results from viral symptoms in the respiratory tract. Here we review the research into the delivery technologies available as well as the types of therapeuticsused for respiratory virus disease and examine how virus infection-induced airway inflammation modulates its success. We discuss the future of aerosol administration and present potential alternative methods for efficientdrug delivery so as to improve post-infection virus control therapies.
    View less >
    Journal Title
    Current Drug Delivery
    Volume
    12
    DOI
    https://doi.org/10.2174/1567201811666140918114528
    Copyright Statement
    © 2015 Bentham Science Publishers. This is the author-manuscript version of this paper. Reproduced in accordance with the copyright policy of the publisher. Please refer to the journal website for access to the definitive, published version.
    Subject
    Immunogenetics (incl. Genetic Immunology)
    Pharmacology and Pharmaceutical Sciences
    Publication URI
    http://hdl.handle.net/10072/138148
    Collection
    • Journal articles

    Footer

    Disclaimer

    • Privacy policy
    • Copyright matters
    • CRICOS Provider - 00233E

    Tagline

    • Gold Coast
    • Logan
    • Brisbane - Queensland, Australia
    First Peoples of Australia
    • Aboriginal
    • Torres Strait Islander